Newly diagnosed hepatitis C: Lack of symptoms doesn't mean lack of progression

Postgraduate Medicine

Volumn 102, Issue 6, 1997, Pages 95-101

  Trivedi, Madhuri ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; RECOMBINANT ALPHA2B INTERFERON;

ALOPECIA; ANOREXIA; CONFERENCE PAPER; DEPRESSION; FEVER; HEPATITIS C; HUMAN; HYPOTHYROIDISM; IMMUNOASSAY; LIVER BIOPSY; MYALGIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031436128     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.12.379     Document Type: Conference Paper

References (15)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244(4902):359-62
2. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995;15(1):82-91
3. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994;23(3):437-55
4. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15(1):5-14
5. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995;122(3):169-73
6. Tedeschi V, Seeff LB. Diagnostic tests for hepatitis C: where are we now? (Editorial) Ann Intern Med 1995;123(5):383-5
7. Shiomi S, Kuroki T, Minamitani S, et al. Effect of drinking on the outcome of cirrhosis in patients with hepatitis B or C. J Gastroenterol Hepatol 1992;7(3):274-6
8. Dhillon AP, Dusheiko GM. Pathology of hepatitis C virus infection. Histopathology 1995;26(4):297-309
9. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21(2):570-83
10. Multicenter Study Group. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332(22):1457-62 [Erratum, N Engl J Med 1996;334(17):1143]
11. Castillo I, Bartolome J, Navas S, et al. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994;19(6):1342-6
12. Watanabe U, Hashimoto E, Hisamitsu T, et al. The risk factor for development of thyroid disease during interferon α therapy for chronic hepatitis C. Am J Gastroenterol 1994;89(3):399-403
13. Hoofnagle JH. Therapy of acute and chronic viral hepatitis. Adv Intern Med 1994;39:241-75
14. Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14(6):969-74
15. Jouet P, Roudot-Thoraval F, Dhumeaux D, et al, for Le Groupe Français pour l'Etude du Traitement des Hepatites Chroniques (NANB/C). Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994;106(3):686-90